MERTK and breast carcinoma: Furthermore, in a significant proportion of primary breast carcinomas from patients experiencing relapse, the diminished expression of miR-335—an identified inhibitor of cancer metastasis calculated to target the 3’-UTR of MERTK possibly explains the Upregulation of MERTK in these susceptible tumors [12].